Government of Canada will support advancement of VBI’s coronavirus program through Phase 2 clinical development Pre-clinical data are expected to enable selection of clinical candidates in Q3 2020 and the...
Read More
Productive pre-submission meetings with FDA and EMA in May and July 2020 expected to enable filings of regulatory approval applications for Sci-B-Vac® in the U.S., Europe, and Canada beginning Q4...
Read More
Confirmed durable partial response with recurrent GBM tumor reduction of more than 50% Normal baseline CD4+/CD8+ T cell ratio identified as potentially predictive biomarker associated with tumor responses AACR data...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will participate in the following...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of a Commercial Advisory Board consisting of leading experts...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has entered into a debt financing facility for up...
Read More
Presentation will highlight expanded immunologic and tumor response data as well as potentially-predictive biomarker data from the VBI-1901 + GM-CSF study arm in Part B of the ongoing Phase 1/2a...
Read More
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering...
Read More